338 related articles for article (PubMed ID: 14565614)
21. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.
Adjé-Touré C; Celestin B; Hanson D; Roels TH; Hertogs K; Larder B; Diomande F; Peeters M; Eholié S; Lackritz E; Chorba T; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S23-9. PubMed ID: 14565606
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
24. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
[TBL] [Abstract][Full Text] [Related]
25. Use of pre-ART laboratory screening to identify renal, hepatic and haematological abnormalities in Côte d'Ivoire.
Minchella PA; Adjé-Touré C; Zhang G; Tehe A; Hedje J; Rottinghaus ER; Natacha K; Diallo K; Ouedraogo GL; Nkengasong JN
Trop Med Int Health; 2020 Apr; 25(4):408-413. PubMed ID: 31960558
[TBL] [Abstract][Full Text] [Related]
26. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings.
Carter RJ; Dugan K; El-Sadr WM; Myer L; Otieno J; Pungpapong N; Toro PL; Abrams EJ;
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):404-10. PubMed ID: 20595905
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
[TBL] [Abstract][Full Text] [Related]
29. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda.
Jain V; Chang W; Byonanebye DM; Owaraganise A; Twinomuhwezi E; Amanyire G; Black D; Marseille E; Kamya MR; Havlir DV; Kahn JG
PLoS One; 2015; 10(12):e0143433. PubMed ID: 26632823
[TBL] [Abstract][Full Text] [Related]
30. CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIV-positive patients on antiretroviral therapy.
Evans DH; Fox MP; Maskew M; McNamara L; MacPhail P; Mathews C; Sanne I
J Int AIDS Soc; 2014; 17(1):19139. PubMed ID: 25227265
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
32. Costs of Care of HIV-Infected Children Initiating Lopinavir/Ritonavir-Based Antiretroviral Therapy before the Age of Two in Cote d'Ivoire.
Desmonde S; Avit D; Petit J; Amorissani Folquet M; Eboua FT; Amani Bosse C; Dainguy E; Mea V; Timite-Konan M; Ngbeché S; Ciaranello A; Leroy V
PLoS One; 2016; 11(12):e0166466. PubMed ID: 27935971
[TBL] [Abstract][Full Text] [Related]
33. High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire.
Ghehi C; Gabillard D; Moh R; Badje A; Kouamé GM; Oouttara E; Ahibo H; N'Takpé JB; Lecarrou J; Eholié SP; Anglaret X; Danel C
PLoS One; 2017; 12(6):e0177440. PubMed ID: 28582393
[TBL] [Abstract][Full Text] [Related]
34. Long-term immunological responses to treatment among HIV-2 patients in Côte d'Ivoire.
Minchella PA; Adjé-Touré C; Zhang G; Tehe A; Hedje J; Rottinghaus ER; Kohemun N; Aka M; Diallo K; Ouedraogo GL; De Cock KM; Nkengasong JN
BMC Infect Dis; 2020 Mar; 20(1):213. PubMed ID: 32164565
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
[TBL] [Abstract][Full Text] [Related]
36. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
Bishai D; Colchero A; Durack DT
AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
[TBL] [Abstract][Full Text] [Related]
37. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
Bwire R; Nagelkerke NJ; Borgdorff MW
Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
[TBL] [Abstract][Full Text] [Related]
38. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults.
Danel C; Moh R; Chaix ML; Gabillard D; Gnokoro J; Diby CJ; Toni T; Dohoun L; Rouzioux C; Bissagnene E; Salamon R; Anglaret X;
J Infect Dis; 2009 Jan; 199(1):66-76. PubMed ID: 18986246
[TBL] [Abstract][Full Text] [Related]
39. Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.
Messou E; Gabillard D; Moh R; Inwoley A; Sorho S; Eholié S; Rouet F; Seyler C; Danel C; Anglaret X
Bull World Health Organ; 2008 Jun; 86(6):435-42. PubMed ID: 18568272
[TBL] [Abstract][Full Text] [Related]
40. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
